Incidence rate of prostate cancer in men treated for erectile dysfunction with phosphodiesterase type 5 inhibitors: retrospective analysis
| Autor: | M. Hasan Rajab, K. Scott Coffield, Chanhee Jo, Anthony H. Chavez |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty Urology Prostatic Hyperplasia Prostate cancer Erectile Dysfunction Risk Factors Internal medicine medicine Humans Aged Retrospective Studies Gynecology business.industry Incidence Medical record Incidence (epidemiology) Prostatic Neoplasms Retrospective cohort study General Medicine Odds ratio Middle Aged Phosphodiesterase 5 Inhibitors Prostate-Specific Antigen medicine.disease Confidence interval Prostate-specific antigen Erectile dysfunction Original Article business |
| Zdroj: | Asian Journal of Andrology. 15:246-248 |
| ISSN: | 1745-7262 1008-682X |
| DOI: | 10.1038/aja.2012.162 |
| Popis: | The purpose of this study was to determine the incidence rate of prostate cancer among men with erectile dysfunction (ED) treated with phosphodiesterase type 5 inhibitors (PDE-5i) over a 7-year period vs. men with ED of the same age and with similar risk factors who were not treated with PDE-5i. In a retrospective review of electronic medical records and billing databases between the years 2000 and 2006, men with ED between the ages of 50 and 69 years and no history of prostate cancer prior to 2000 were identified. These individuals were divided into two groups: 2362 men who had treatment with PDE-5i, and 2612 men who did not have treatment. Demographic data in each group were compared. During the study period, 97 (4.1%) men with ED treated with PDE-5i were diagnosed with prostate cancer compared with 258 (9.9%) men with ED in the non-treated group (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|